Pharmagen Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2013	FY 2012	FY 2011	FY 2010
Period Ending	Mar '14 Mar 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012	Dec '11 Dec 31, 2011	Dec '10 Dec 31, 2010
Revenue	4.41	4.81	4.26	0.86	0.08
Revenue Growth (YoY)	-19.85%	12.97%	393.84%	1045.67%	-
Cost of Revenue	1.66	1.77	3	0.45	0.01
Gross Profit	2.75	3.05	1.26	0.41	0.07
Selling, General & Admin	4.99	5.2	3.36	0.69	0.07
Operating Expenses	4.99	5.2	3.36	0.69	0.07
Operating Income	-2.24	-2.16	-2.1	-0.28	-0
Interest Expense	-3.02	-3.01	-0.77	-0.01	-0.01
Other Non Operating Income (Expenses)	0.87	0.63	0.09	-	-
EBT Excluding Unusual Items	-4.39	-4.53	-2.77	-0.3	-0.01
Impairment of Goodwill	-1.2	-1.2	-	-	-
Other Unusual Items	-0.29	-0.27	-	-	-
Pretax Income	-5.87	-6	-2.77	-0.3	-0.01
Net Income	-5.87	-6	-2.77	-0.3	-0.01
Preferred Dividends & Other Adjustments	0.56	0.46	-	-	-
Net Income to Common	-6.43	-6.46	-2.77	-0.3	-0.01
Shares Outstanding (Basic)	408	384	351	200	-
Shares Outstanding (Diluted)	408	384	351	200	-
Shares Change (YoY)	8.65%	9.24%	75.54%	-	-
EPS (Basic)	-0.02	-0.02	-0.01	-0.00	-
EPS (Diluted)	-0.02	-0.02	-0.01	-0.00	-
Free Cash Flow	-0.59	-0.75	-2.28	-0.31	0.01
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.00	-
Gross Margin	62.27%	63.27%	29.68%	47.43%	87.71%
Operating Margin	-50.83%	-44.86%	-49.20%	-32.75%	-2.80%
Profit Margin	-145.73%	-134.17%	-65.04%	-34.40%	-12.39%
Free Cash Flow Margin	-13.28%	-15.56%	-53.41%	-36.10%	9.36%
EBITDA	-2.13	-2.06	-2.06	-0.26	-
EBITDA Margin	-48.31%	-42.79%	-48.43%	-29.59%	-
D&A For EBITDA	0.11	0.1	0.03	0.03	-
EBIT	-2.24	-2.16	-2.1	-0.28	-0
EBIT Margin	-50.83%	-44.86%	-49.20%	-32.75%	-2.80%
Revenue as Reported	4.81	4.81	4.26	-	0.08
Advertising Expenses	-	0.19	0.43	0.01	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.